HANGZHOU AGS MEDTECH CO., LTD. Financials Hangzhou AGS MedTech Co., Ltd.
Equities
688581
CNE100005ZF0
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 82.12 CNY | -2.24% |
|
-2.09% | -34.20% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 7,223 | 4,731 | - | - |
| Enterprise Value (EV) 1 | 7,223 | 4,731 | 4,731 | 4,731 |
| P/E ratio | 29.8 x | 18.7 x | 13.7 x | 10.6 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 14.2 x | 7.11 x | 5.37 x | 4.09 x |
| EV / Revenue | 14.2 x | 7.11 x | 5.37 x | 4.09 x |
| EV / EBITDA | 27.9 x | 16.8 x | 12.8 x | 9.73 x |
| EV / FCF | 42,497,490 x | - | - | - |
| FCF Yield | 0% | - | - | - |
| Price to Book | 3.27 x | 1.96 x | 1.74 x | 1.52 x |
| Nbr of stocks (in thousands) | 57,871 | 57,611 | - | - |
| Reference price 2 | 124.8 | 82.12 | 82.12 | 82.12 |
| Announcement Date | 2/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 508.7 | 665.8 | 880.7 | 1,157 |
| EBITDA 1 | - | 258.9 | 281.5 | 370.5 | 486 |
| EBIT 1 | - | 252.2 | 313.5 | 402.5 | 520.5 |
| Operating Margin | - | 49.58% | 47.09% | 45.7% | 45% |
| Earnings before Tax (EBT) 1 | - | 251.7 | 314.5 | 403.5 | 521.5 |
| Net income 1 | 145 | 217.2 | 270.5 | 347 | 448 |
| Net margin | - | 42.7% | 40.63% | 39.4% | 38.73% |
| EPS 2 | 3.340 | 4.190 | 4.400 | 5.995 | 7.735 |
| Free Cash Flow | - | 170 | - | - | - |
| FCF margin | - | 33.41% | - | - | - |
| FCF Conversion (EBITDA) | - | 65.65% | - | - | - |
| FCF Conversion (Net income) | - | 78.24% | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/26/23 | 2/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | 170 | - | - | - |
| ROE (net income / shareholders' equity) | - | 15.2% | 11.2% | 12.7% | 14.3% |
| ROA (Net income/ Total Assets) | - | 15.5% | 10.8% | 12.2% | 13.5% |
| Assets 1 | - | 1,405 | 2,505 | 2,854 | 3,319 |
| Book Value Per Share 2 | - | 38.20 | 41.90 | 47.30 | 54.10 |
| Cash Flow per Share 2 | - | 3.830 | 4.460 | 5.670 | 7.520 |
| Capex 1 | - | 51.5 | 70 | 50 | 40 |
| Capex / Sales | - | 10.12% | 10.51% | 5.68% | 3.46% |
| Announcement Date | 4/26/23 | 2/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
82.12
CNY
Average target price
122.5
CNY
Spread / Average Target
+49.17%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -34.20% | 655M | |
| +11.73% | 226B | |
| +9.53% | 188B | |
| +14.63% | 137B | |
| +27.47% | 108B | |
| -0.04% | 63.19B | |
| +13.73% | 52.26B | |
| +4.86% | 51B | |
| +7.72% | 43.89B | |
| +7.86% | 38.07B |
- Stock Market
- Equities
- 688581 Stock
- Financials Hangzhou AGS MedTech Co., Ltd.
